Gujarat Themis Biosyn Limited
Quant Mutual Fund increased its stake in Gujarat Themis Biosyn from 1.15% to 7.47%, acquiring 84,74,577 shares to cross the 5% disclosure threshold.
A pharmaceutical manufacturer incorporated in 1981, Gujarat Themis Biosyn produces finished Active Pharmaceutical Ingredients through advanced fermentation-based processes. The company specializes in biosynthetic drug compounds for both domestic and international markets. Its proprietary fermentation expertise, vertical integration in API manufacturing, and focus on complex molecule production distinguish it within India's competitive pharmaceutical sector.
Built a quantitative, data-driven investment philosophy in an industry dominated by discretionary stock pickers. Manages over Rs 1.2 lakh crore. Founded by Sanjeev Sharma, Quant MF uses VLRT (Valuation, Liquidity, Risk, and Time) framework to run high-turnover, tactically active portfolios. Grew from obscurity to one of India's top-15 AMCs in under five years, attracting both retail capital and scrutiny for its aggressive churn.